Evaluation of the Effects of Anti-TNF Therapy on the Retina in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis

November 10, 2026 updated by: Muhammet Ali Gürsoy, Ankara City Hospital Bilkent

EVALUATION OF THE EFFECTS OF ANTI-TNF THERAPY ON THE RETINA IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS

This prospective observational cohort study evaluates whether anti-tumor necrosis factor (anti-TNF) therapy changes the retinal and choroidal microvasculature and retinal structure in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS). Patients for whom the rheumatology clinic decided to start anti-TNF therapy as part of routine care are compared with patients who continue treatment without anti-TNF agents. All participants undergo a complete eye examination, optical coherence tomography (OCT) and OCT angiography (OCTA) before treatment and at month 6. The main question is whether retinal vessel density changes differently over time between the two groups.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Background: Chronic systemic inflammation in RA and AS has been associated with endothelial dysfunction and microvascular changes. TNF-alpha is a key mediator of this inflammation, and anti-TNF agents are widely used in both diseases. Prospective data on retinal and choroidal microvasculature with measurements taken before the start of anti-TNF therapy are limited.

Design and participants: Patients with RA or AS followed at the Rheumatology Clinic of Ankara Bilkent City Hospital were referred to the Ophthalmology Clinic between October and December 2025. Treatment decisions were made by the treating rheumatologists, independently of the study. The anti-TNF group consists of anti-TNF-naive patients for whom anti-TNF therapy was planned; their baseline examination was performed before the first dose. The control group consists of patients who were not receiving anti-TNF therapy at baseline and did not start it during the 6-month follow-up.

Assessments: At baseline and month 6, all participants undergo best-corrected visual acuity (logMAR), Goldmann applanation tonometry, slit-lamp biomicroscopy and dilated fundus examination with a +90 D lens. OCT (Heidelberg Spectralis) is used to measure central and sectoral macular thickness, peripapillary retinal nerve fiber layer (RNFL) thickness (global and six sectors) and ganglion cell layer (GCL) thickness. OCTA (RTVue XR Avanti with AngioVue, Optovue) is performed with fovea-centred 6x6 mm scans. Superficial (SCP) and deep capillary plexus (DCP) vessel density are recorded for the whole image, superior and inferior hemifields, and foveal, parafoveal and perifoveal regions with four sectors. Foveal avascular zone (FAZ) area, FAZ perimeter, acircularity index, foveal vessel density and choriocapillaris flow area are also recorded. 3D projection artifact removal is applied. Scans with a quality (Q) score below 6, significant motion or projection artifacts, or segmentation errors are excluded. All examinations are performed by the same, unmasked examiner. ESR and CRP values closest to each visit are obtained from hospital records.

Statistical analysis: Eye-level data are analysed with linear mixed models adjusted for age and sex. The treatment effect is assessed by the group-by-time interaction. The study is reported according to the STROBE guideline.

Study Type

Observational

Enrollment (Actual)

53

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patients with rheumatoid arthritis or ankylosing spondylitis followed at the Rheumatology Clinic of Ankara Bilkent City Hospital and referred to the Ophthalmology Clinic between October and December 2025.

Description

Inclusion Criteria:

  • Age 18 to 75 years
  • Diagnosis of rheumatoid arthritis or ankylosing spondylitis
  • Receiving treatment for RA or AS (conventional therapy, planned initiation of anti-TNF therapy, or continued conventional non-biologic therapy)
  • Willingness to participate and written informed consent

Exclusion Criteria:

  • • History of retinal disease (e.g., diabetic retinopathy, age-related macular degeneration, retinal vein occlusion)

    • Ocular disease that may affect OCT measurements or visual field, such as glaucoma, optic neuropathy or dense cataract
    • Uveitis, diabetes mellitus or systemic hypertension
    • Previous ocular surgery or laser treatment, or high refractive error
    • Pregnancy or breastfeeding
    • Treatment with non-TNF biologic agents (e.g., abatacept, rituximab)
    • OCTA scan quality (Q) score below 6

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Anti-TNF group

Anti-TNF-naive patients with RA or AS for whom the treating rheumatologist planned to start anti-TNF therapy as part of routine care. The baseline examination was performed before the first dose.

adalimumab, etanercept, golimumab

Other Names:
  • TNF inhibitor prescribed by the treating rheumatologist according to routine clinical practice; not assigned by the study protocol.
Control group

Patients with RA or AS who were not receiving anti-TNF therapy at baseline and did not start it during the 6-month follow-up. They continued conventional (non-biologic) treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in superficial capillary plexus whole-image vessel density
Time Frame: Baseline and month 6

SCP vessel density (%) in fovea-centred 6x6 mm OCTA scans (AngioVue, Optovue). Change from baseline to month 6 is compared between groups (group-by-time interaction).

Baseline and month 6
Change in deep capillary plexus whole-image vessel density
Time Frame: Baseline and month 6

DCP vessel density (%) in fovea-centred 6x6 mm OCTA scans. Change from baseline to month 6 is compared between groups.

Baseline and month 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Erythrocyte sedimentation (mm/h) rate
Time Frame: Baseline and month 6

Change in systemic inflammatory marker obtained from hospital records.

Baseline and month 6
C-reactive protein (mg/L) value
Time Frame: Baseline and month 6

Change in systemic inflammatory marker obtained from hospital records.

Baseline and month 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Yasin Toklu, Professor Doctor, Ankara City Hospital Bilkent

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 25, 2025

Primary Completion (Actual)

June 23, 2026

Study Completion (Actual)

June 23, 2026

Study Registration Dates

First Submitted

October 18, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 12, 2026

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • TABED 1-25-1729

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared publicly. Aggregate results will be reported in scientific publications.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.